Target intelligence / Profile preview

Hemagglutinin protein subtype H5 (H5 HA)

Target: H5 HA
Molecular classification: Glycoprotein, Viral surface protein, Class I fusion protein, Receptor-binding protein

Overview

The **Hemagglutinin protein subtype H5** is a trimeric, integral membrane glycoprotein that mediates viral entry for influenza A viruses of the H5 serotype. Each monomer consists of HA1 (globular head, receptor binding) and HA2 (stem, fusion peptide) regions, generated by cleavage of the precursor HA0 by host proteases—a requirement for infectivity[1][3]. HA1 binds sialic acid receptors on host cells, while HA2 mediates fusion of viral and cellular membranes, initiating infection[1][2][3]. Antigenic variation in H5 HA underlies viral escape from immunity and poses challenges for vaccine design. H5 HA is the principal antigenic target for neutralizing antibodies and is a critical determinant of host range, transmissibility, and pathogenicity in both avian and mammalian hosts[2][3].

Other names: H5 hemagglutininH5 subtype HAInfluenza A virus H5 HAHA subtype H5

Mechanism of action

Drugs/antibodies inhibit receptor binding and/or fusion activity to block virus entry\nNeutralization by antibodies can prevent cell infection by sterically blocking attachment or fusion

Biological functions

Viral attachment to host cellMembrane fusion (virus-cell entry)Antigenic determinant

Disease associations

Infection (major role in avian influenza H5N1 and other H5 subtype outbreaks)Transmission and virulence (key determinant of host specificity and pathogenicity)

Safety considerations

Antigenic drift: high mutation rate leads to escape from immune detection and limits durability of therapeutics/vaccinesRisk of enhanced virulence: some HA sequence changes associated with increased pathogenicity and zoonotic transmissionCross-reactivity: potential for immune responses against similar, non-target HAs in broad-spectrum therapies

Interacting drugs

Monoclonal antibodies (e.g., FLD194, as referenced in structural studies)

1 more in the full profile.

Biomarkers

Anti-HA antibody titers (used in efficacy monitoring of H5 influenza vaccination or infection)Sequence variation in H5 HA can be used for subtyping, epidemiology, and selection for targeted therapies

Beyond the preview

Go deeper on Hemagglutinin protein subtype H5 (H5 HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemagglutinin protein subtype H5 (H5 HA).

Explore the full profile